表紙:家族性アミロイドニューロパチー:開発中の薬剤
市場調査レポート
商品コード
362374

家族性アミロイドニューロパチー:開発中の薬剤

Familial Amyloid Neuropathies (Metabolic Disorder) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 96 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
家族性アミロイドニューロパチー:開発中の薬剤
出版日: 2021年12月30日
発行: Global Markets Direct
ページ情報: 英文 96 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、家族性アミロイドニューロパチー治療薬の開発状況について調査しており、パイプライン製品の概要、治験段階別の製品概要、主要企業および薬剤のプロファイル、パイプライン製品の最新動向、および最新ニュース/プレスリリースなどを提供しています。

イントロダクション

  • 調査範囲

家族性アミロイドニューロパチーの概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

家族性アミロイドニューロパチー:企業で開発中の治療薬

家族性アミロイドニューロパチー:大学/機関で研究中の治療薬

家族性アミロイドニューロパチー:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

家族性アミロイドニューロパチー:企業で開発中の製品

家族性アミロイドニューロパチー:大学/機関で研究中の製品

家族性アミロイドニューロパチーの治療薬開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Bsim2
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • SOM Innovation Biotech SL

家族性アミロイドニューロパチー:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

家族性アミロイドニューロパチー:最近のパイプライン動向

家族性アミロイドニューロパチー:休止中のプロジェクト

家族性アミロイドニューロパチー:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Familial Amyloid Neuropathies, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Familial Amyloid Neuropathies - Pipeline by ADRx Inc, 2021
  • Familial Amyloid Neuropathies - Pipeline by Akcea Therapeutics Inc, 2021
  • Familial Amyloid Neuropathies - Pipeline by Alnylam Pharmaceuticals Inc, 2021
  • Familial Amyloid Neuropathies - Pipeline by BSIM Therapeutics SA, 2021
  • Familial Amyloid Neuropathies - Pipeline by Corino Therapeutics Inc, 2021
  • Familial Amyloid Neuropathies - Pipeline by Novo Nordisk AS, 2021
  • Familial Amyloid Neuropathies - Pipeline by Precision Biosciences Inc, 2021
  • Familial Amyloid Neuropathies - Pipeline by Proclara Biosciences Inc, 2021
  • Familial Amyloid Neuropathies - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Familial Amyloid Neuropathies - Dormant Projects, 2021
  • Familial Amyloid Neuropathies - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Familial Amyloid Neuropathies, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13197IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Amyloid Neuropathies - Drugs In Development, 2021, provides an overview of the Familial Amyloid Neuropathies (Metabolic Disorders) pipeline landscape.

Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness, and fainting. Supportive treatment includes diuretics, calcium channel blockers, beta blockers, angiotensin receptor blockers and angiotensin converting enzyme (ACE) inhibitors.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Amyloid Neuropathies - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 3, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Amyloid Neuropathies (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Familial Amyloid Neuropathies - Overview
  • Familial Amyloid Neuropathies - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Familial Amyloid Neuropathies - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Familial Amyloid Neuropathies - Companies Involved in Therapeutics Development
  • Familial Amyloid Neuropathies - Drug Profiles
  • Familial Amyloid Neuropathies - Dormant Projects
  • Familial Amyloid Neuropathies - Discontinued Products
  • Familial Amyloid Neuropathies - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer